Author:
Rhee Chin Kook,Lee Sang Haak,Kim Ju Sang,Kim Seung Joon,Kim Seok Chan,Kim Young Kyoon,Kang Hyun Hee,Yoon Hyoung Kyu,Song Jeong Sup,Moon Hwa Sik,Kim Jin Woo,Kim Chi Hong,Shim Byoung Yong,Kim Hoon Kyo,Sun Der Sheng,Kim Kwan Hyoung
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference22 articles.
1. Management of small-cell lung cancer: incremental changes but hope for the future;Hann;Oncology,2008
2. CKD-602. Chong Kun Dang;Crul;Curr Opin Investing Drugs,2003
3. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor;Lee;Arch Pharm Res,1998
4. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative;Lee;Ann N Y Acad Sci,2000
5. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer;Kim;Lung Cancer,2010
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献